An overview on -Indigenous and Conventional Treatment for Pemphigus
DOI:
https://doi.org/10.63671/ijsssr.v1i3.55Keywords:
Corticosteroid, Desmoglein, IgG autoantibodies, Pemphigus foliaceus, Pemphigus vulgarisAbstract
Pempigus encompasses autoimmune bullous conditions, which affect both mucous membranes and the skin. The condition commonly runs a chronic-relapsing cours, with a potentially ruinous on the patient’s quality of life. Pempigus pathogenesis is related to IgG autoantibodies targeting several adhesion molecules in the epidermis, including desmogelin (Dsg) 1 and 3, major elements of desmosomes. Clinical operation of pemphigus is beginning to move down from broad-range immunosuppression and towards B-cell targeted curatives, which reduce numerous cases symptoms but can have significant side effects. Then we’ve review the threat factors regarding pemphigus. The remedies should be specified only when proper diagnosed is done. Both conventional and modernistic methods of recovery remedy have been discussed.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 International Journal of Science and Social Science Research

This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
Similar Articles
- Vedant Shaligram, Anwar Shaikh, An Overview on Pharmacological Activity of Bambusa Vulgaris , International Journal of Science and Social Science Research: Vol. 1 No. 4: January-March 2024
- Shailendra Vikram Singh, Mukul Dutta Pandey, Neha Singh, Analysing the Nutrient Uptake and Economic Viability of Integrated Nutrient Management for French Bean (Phaseolus vulgaris L.) in Uttar Pradesh Gangetic Plain , International Journal of Science and Social Science Research: Vol. 3 No. 1: April-June 2025
You may also start an advanced similarity search for this article.
Most read articles by the same author(s)
- Uttam Dube, Gaurav Madke, Yogesh Kumbhar, Vitex negundo a plant with multi- Pharmacological benefits , International Journal of Science and Social Science Research: Vol. 1 No. 4: January-March 2024
